Reconstitution raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual descriptor; not a measure of purity |
| Solubility class | Freely soluble in water | Aqueous dissolution may require gentle mixing |
| Typical storage (powder) | −20 °C or below, desiccated | Protect from light and ambient moisture |
| Typical storage (solution) | 2–8 °C, short term | Freeze aliquots where longer holding is needed |
| Purity assessment | Reversed-phase HPLC, area percent | Values depend on column, gradient, and detection wavelength |
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
== Decay == Thorium-232 has a half-life of 14 billion years; it is itself an essentially pure alpha emitter with its first decay product radium-228. Radium-228 is itself unstable and leads to a decay chain known as the thorium series, which terminates at stable lead-208. The intermediates in the thorium-232 decay chain are all relatively short-lived; the longest-lived intermediate decay products are radium-228 and thorium-228, with half-lives of 5.75 years and 1.91 years, respectively. All others have half-lives under four days. The main decay branches are shown below:
== Background == Bhagwat Singh Mewar was a patron of numerous trusts throughout his lifetime. On 20 October 1969, he founded the MMCF by providing a substantial endowment and donating key sections of the City Palace in Udaipur for its establishment. In his will and testament of 1984, he reconstituted the institution of the Maharana for the MMCF, so that the office of Maharana shall continue in perpetuity. After his death, his son Arvind Singh Mewar was appointed Chairman and Managing Trustee of the MMCF. Following the death of Arvind Singh Mewar on 16 March 2025, his son, Lakshyaraj Singh Mewar, now functions as the Managing Trustee of the trust.
The team is commonly known as Los Cafeteros ("The Coffee Growers"), after Colombia's coffee industry, and as La Tricolor, after the yellow, blue and red of the national flag. The Colombian state broadcaster's archive service has described the shirt as having become "a new national symbol", worn across regions and social classes on match days. Colombia's yellow shirt, blue shorts and red socks are a relatively recent settlement rather than an inherited palette. Early sides alternated white and blue, with white worn at the 1945 South American Championship and dark blue at the 1962 FIFA World Cup. From 1971 the team wore orange, known domestically as zapote. In 1985 the Colombian Football Federation commissioned the designer María Elvira Pardo to base a kit on the national flag; her design made red the first-choice shirt, worn through the 1990 FIFA World Cup, with yellow as the alternative. Yellow was promoted to first choice in the early 1990s. Subsequent departures have been tournament-specific: a red change kit at the 2014 FIFA World Cup referencing the 1990s alternates, and a white first-choice shirt at the Copa América Centenario echoing the 1945 side. Adidas has supplied the team since January 2011 under an agreement signed in November 2010, subsequently extended to 2030; earlier suppliers included Le Coq Sportif, Adidas, Puma, Kelme, Umbro, Reebok and Lotto.
The current NIOSH definition for an IDLH condition, as given in the NIOSH Respirator Selection Logic, is one that poses a threat of exposure to airborne contaminants when that exposure is likely to cause death or immediate or delayed permanent adverse health effects or prevent escape from such an environment. The purpose of establishing an IDLH value is (1) to ensure that the worker can escape from a given contaminated environment in the event of failure of the respiratory protection equipment and (2) is considered a maximum level above which only a highly reliable breathing apparatus providing maximum worker protection is permitted. In September 1995, NIOSH issued a new policy for developing recommended exposure limits (RELs) for substances, including carcinogens. As benzene can cause cancer, NIOSH recommends that all workers wear special breathing equipment when they are likely to be exposed to benzene at levels exceeding the REL (10-hour) of 0.1 ppm. The NIOSH short-term exposure limit (STEL – 15 min) is 1 ppm. American Conference of Governmental Industrial Hygienists (ACGIH) adopted Threshold Limit Values (TLVs) for benzene at 0.02 ppm TWA in 2024. The European Union exposure limit value for benzene is 0.66 mg/m3. Germany's acceptable concentration (AC) is 0.2 mg/m3 and tolerable concentration (TC) is 1.9 mg/m3, where 1 mg/m3 is about 1 ppm in air.
Sources: en.wikipedia.org
Electronic excitation spectroscopy, or ultraviolet-visible (UV-vis) spectroscopy, is performed in the visible and ultraviolet regions of the electromagnetic spectrum and is useful for probing the difference in energy between the highest energy occupied (HOMO) and lowest energy unoccupied (LUMO) molecular orbitals. This information is useful to physical organic chemists in the design of organic photochemical systems and dyes, as absorption of different wavelengths of visible light give organic molecules color. A detailed understanding of an electronic structure is therefore helpful in explaining electronic excitations, and through careful control of molecular structure it is possible to tune the HOMO–LUMO gap to give desired colors and excited state properties.
This assumption arose from the dopamine hypothesis that maintains that both schizophrenia and bipolar disorder are a result of excessive dopamine activity. Furthermore, psychomotor stimulants like cocaine that increase dopamine levels can cause psychotic symptoms if taken in excess. Chlorpromazine and other typical antipsychotics are primarily blockers of D2 receptors. An almost perfect correlation exists between the therapeutic dose of a typical antipsychotic and the drug's affinity for the D2 receptor. Therefore, a larger dose is required if the drug's affinity for the D2 receptor is relatively weak. A correlation exists between average clinical potency and affinity of the antipsychotics for dopamine receptors. Chlorpromazine tends to have a greater effect at serotonin receptors than at D2 receptors, which is notably the opposite effect of the other typical antipsychotics. Therefore, chlorpromazine's effects on dopamine and serotonin receptors are more similar to the atypical antipsychotics than to the typical antipsychotics. Chlorpromazine and other antipsychotics with sedative properties such as promazine and thioridazine are among the most potent agents at α-adrenergic receptors. Furthermore, they are also among the most potent antipsychotics at histamine H1 receptors. This finding is in agreement with the pharmaceutical development of chlorpromazine and other antipsychotics as anti-histamine agents.
== Interactions == CYP3A4 inhibitors can increase exposure to suvorexant while CYP3A4 inducers can decrease exposure to suvorexant. Combination of suvorexant with the strong CYP3A4 inhibitor ketoconazole increased suvorexant overall exposure by 2.79-fold and peak levels by about 1.25-fold, combination with the moderate CYP3A4 inhibitor diltiazem increased suvorexant overall exposure by 2.05-fold and peak levels by about 1.25-fold, and combination with the strong CYP3A4 inducer rifampin decreased suvorexant overall exposure by 88% and peak levels by about 65%. The elimination half-life of suvorexant (about 12 hours for suvorexant alone) was increased to 19.4 hours with ketoconazole and to 16.1 hours with diltiazem while it was decreased to 7.7 hours with rifampin. Concomitant use of suvorexant with strong CYP3A4 inhibitors is not recommended, while lower doses of suvorexant are recommended with moderate CYP3A4 inhibitors (5 mg starting dose and 10 mg maximum dose generally). The substantial decrease in suvorexant exposure with strong CYP3A4 inducers may result in loss of effectiveness. Suvorexant does not appear to have been assessed in combination with moderate CYP3A4 inducers (e.g., modafinil).
Sources: en.wikipedia.org
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.
There is no single agreed limit, and laboratory practice varies widely. Refrigeration slows degradation, and freezing aliquots is often described for longer holding. Any visible cloudiness or precipitate indicates the solution should be discarded.
Mass spectrometry provides the most direct confirmation through molecular mass. Reversed-phase chromatography supports purity assessment, and peptide mapping or amino acid analysis can corroborate sequence. No single method establishes both purity and identity on its own.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.